Endostatin influences endothelial morphology via the activated ERK1/2-kinase endothelial morphology and signal transduction

Microvascular Research

Volumn 71, Issue 3, 2006, Pages 152-162

  Schmidt, Annette ^a   Wenzel, Daniela ^e   Thorey, Irmgard ^c   Sasaki, Takako ^d   Hescheler, Jürgen ^b   Timpl, Rupert ^d   Addicks, Klaus ^b   Werner, Sabine ^c   Fleischmann, Bernd K ^e   Bloch, Wilhelm ^a,e  

^a GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c ETH ZURICH   (Switzerland)

^d MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^e UNIVERSITY OF BONN   (Germany)

Author keywords

Endostatin; Endothelial morphology; ERK1 2 kinase; Protein phosphatase 2A; Restin

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ENDOSTATIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOPROTEIN PHOSPHATASE 2A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL STRUCTURE; EMBRYO DEVELOPMENT; ENDOTHELIUM CELL; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANIMALS; CELLS, CULTURED; ENDOSTATINS; ENDOTHELIAL CELLS; FEMALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICROTUBULE-ASSOCIATED PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM PROTEINS; NEOVASCULARIZATION, PHYSIOLOGIC; RECOMBINANT PROTEINS; WOUND HEALING;

EID: 33744537527     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2006.01.001     Document Type: Article

References (35)

1. Abdollahi A., Hahnfeldt P., Maercker C., Grone H.J., Debus J., Ansorge W., Folkman J., Hlatky L., and Huber P.E. Endostatin's antiangiogenic signaling network. Mol. Cell 13 (2004) 649-663
2. Ambler C.A., Schmunk G.M., and Bautch V.L. Stem cell-derived endothelial cells/progenitors migrate and pattern in the embryo using the VEGF signaling pathway. Dev. Biol. 257 (2003) 205-219
3. Andrew P.J., and Mayer B. Enzymatic function of nitric oxide synthases. Cardiovasc. Res. 43 (1999) 521-531
4. Berger A.C., Feldman A.L., Gnant M.F., Kruger E.A., Sim B.K., Hewitt S., Figg W.D., Alexander H.R., and Libutti S.K. The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing. J. Surg. Res. 91 (2000) 26-31
5. Bloch W., Huggel K., Sasaki T., Grose R., Bugnon P., Addicks K., Timpl R., and Werner S. The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. FASEB J. 14 (2000) 2373-2376
6. Boehm T., Folkman J., Browder T., and O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 290 (1997) 404-407
7. Dixelius J., Larsson H., Sasaki T., Holmqvist K., Lu L., Engstrom A., Timpl R., Welsh M., and Claesson-Welsh L. Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood 95 (2000) 3403-3411
8. Doetschman T.C., Eistetter H., Katz M., Schmidt W., and Kemler R. The in vitro development of blastocyst-derived embryonic stem cell lines: formation of visceral yolk sac, blood islands and myocardium. J. Embryol. Exp. Morphol. 87 (1985) 27-45
9. Fassler R., Rohwedel J., Maltsev V., Bloch W., Lentini S., Guan K., Gullberg D., Hescheler J., Addicks K., and Wobus A.M. Differentiation and integrity of cardiac muscle cells are impaired in the absence of beta 1 integrin. J. Cell Sci. 109 (1996) 2989-2999
10. Ignarro L.J. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ. Res. 65 (1989) 1-21
11. Ilan N., Mahooti S., and Madri J.A. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. J. Cell Sci. 111 Pt. 24 (1998) 3621-3631
12. Jiang L., Jha V., Dhanabal M., Sukhatme V.P., and Alper S.L. Intracellular Ca(2+) signaling in endothelial cells by the angiogenesis inhibitors endostatin and angiostatin. Am. J. Physiol., Cell Physiol. 280 (2001) 1140-1150
13. Kazemi S., Wenzel D., Kolossov E., Lenka N., Raible A., Sasse P., Hescheler J., Addicks K., Fleischmann B.K., and Bloch W. Differential role of bFGF and VEGF for vasculogenesis. Cell. Physiol. Biochem. 12 (2002) 55-62
14. Kim Y.M., Hwang S., Kim Y.M., Pyun B.J., Kim T.Y., Lee S.T., Gho Y.S., and Kwon Y.G. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J. Biol. Chem. 277 (2002) 27872-27879
15. Kone B.C. Protein-protein interactions controlling nitric oxide synthases. Acta Physiol. Scand. 168 (2000) 27-31
16. Lai R., Estey E., Shen Y., Despa S., Kantarjian H., Beran M., Maushouri T., Quackenbuch R.C., Keating M., and Albitar M. Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome. Cancer 2002 (2002) 1
17. Miosge N., Sasaki T., and Timpl R. Angiogenesis inhibitor endostatin is a distinct component of elastic fibers in vessel walls. FASEB J. 13 (1999) 1743-1750
18. Morbidelli L., Chang C.H., Douglas J.G., Granger H.J., Ledda F., and Ziche M. Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. Am. J. Physiol. 270 (1996) H411-H415
19. Mundhenke C., Thomas J.P., Wilding G., Lee F.T., Kelzc F., Chappell R., Neider R., Sebree L.A., and Friedl A. Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. Clin. Cancer Res. 7 (2001) 3366-3374
20. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., and Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
21. Orr A.W., Pallero M.A., and Murphy-Ullrich J.E. Thrombospondin stimulates focal adhesion disassembly through Gi- and phosphoinositide 3-kinase-dependent ERK activation. J. Biol. Chem. 277 (2002) 20453-20460
22. Parenti A., Morbidelli L., Cui X.L., Douglas J.G., Hood J.D., Granger H.J., Ledda F., and Ziche M. Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase1/2 activation in postcapillary endothelium. J. Biol. Chem. 273 (1998) 4220-4226
23. Pufe T., Petersen W.J., Miosge N., Goldring M.B., Mentlein R., Varoga D.J., and Tillmann B.N. Endostatin/collagen XVIII - an inhibitor of angiogenesis - is expressed in cartilage and fibrocartilage. Matrix Biol. 23 (2004) 267-276
24. Ramchandran R., Dhanabal M., Volk R., Waterman M.J., Segal M., Lu H., Knebelmann B., and Sukhatme V.P. Antiangiogenic activity of restin, NC10 domain of human collagen XV comparison to endostatin. Biochem. Biophys. Res. Commun. 255 (1999) 735-739
25. Read T.A., Farhadi M., Bjerkvig R., Olsen B.R., Rokstad A.M., Huszthy P.C., and Vajkoczy P. Intravital microscopy reveals novel antivascular and antitumor effects of endostatin delivered locally by alginate-encapsulated cells. Cancer Res. 61 (2001) 6830-6837
26. Redlitz A., Daum G., and Sage E.H. Angiostatin diminishes activation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular endothelial cells. J. Vasc. Res. 36 (1999) 28-34
27. Sasaki T., Fukai N., Mann K., Gohring W., Olsen B.R., and Timpl R. Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. EMBO J. 17 (1998) 4249-4256
28. Sasaki T., Larsson H., Tisi D., Claesson-Welsh L., Hohenester E., and Timpl R. Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity. J. Mol. Biol. 201 (2000) 1179-1190
29. Schmidt A., Wenzel D., Ferring I., Kazemi S., Sasaki T., Hescheler J., Timpl R., Addicks K., Fleischmann B.K., and Bloch W. Influence of endostatin on embryonic vasculo- and angiogenesis. Dev. Dyn. 230 (2004) 468-480
30. Shichiri M., and Hirata Y. Antiangiogenesis signals by endostatin. FASEB J. 15 (2001) 1044-1053
31. Urbich C., Reissner A., Chavakis E., Dernbach E., Haendeler J., Fleming I., Zeiher A.M., Kaszkin M., and Dimmeler S. Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin. FASEB J. 16 (2002) 706-708
32. Urbich C., Reissner A., Chavakis E., Dernbach E., Haendeler J., Fleming I., Zeiher A.M., Kaszkin M., and Dimmeler S. Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin. FASEB J. 16 (2002) 206-208
33. Venema R.C., Venema V.J., Ju H., Harris M.B., Snead C., Jilling T., Dimitropoulou C., Maragoudakis M.E., and Catravas J.D. Novel complexes of guanylate cyclase with heat shock protein 90 and nitric oxide synthase. Am. J. Physiol. Heart Circ. Physiol. 285 (2003) H669-H678
34. Werner S., Smola H., Liao X., Longaker M.T., Krieg T., Hofschneider P.H., and Williams L.T. The function of KGF in morphogenesis of epithelium and reepithelialization of wounds. Science 266 (1994) 819-822
35. Wu H.M., Huang Q., Yuan Y., and Granger H.J. VEGF induces NO-dependent hyperpermeability in coronary venules. Am. J. Physiol. 271 (1996) H2735-H2739